文献速递类风湿关节炎

类风湿关节炎患者生物制剂与Janus激酶抑制剂的药物留存率:ANSWER队列研究

Drug retention of biologics and Janus kinase inhibitors in patients with rheumatoid arthritis: the ANSWER cohort study.
PubMed 文献 · RMD Open · 2023-01-01

这项日本多中心回顾性研究纳入6666个治疗疗程,评估类风湿关节炎患者中生物制剂与Janus激酶抑制剂的药物留存情况。结果显示,因无效停药风险TNFi最高,总体停药风险TNFi和CTLA4-Ig高于aIL-6R。

要点

  • 因无效停药风险:TNFi、CTLA4-Ig、JAKi均高于aIL-6R
  • 因毒性不良事件停药风险:TNFi和aIL-6R均高于CTLA4-Ig
  • 基线口服糖皮质激素与TNFi因无效停药及JAKi、TNFi因毒性停药风险升高相关

核心结论

  • TNFi和CTLA4-Ig总体停药率(排除非毒性和缓解)高于aIL-6R,TNFi的HR=1.52(95%CI:1.37至1.68),CTLA4-Ig的HR=1.14(95%CI:1.00至1.30)。

研究设计与样本

  • 日本多中心回顾性研究,纳入6666个治疗疗程,其中bDMARD初治或JAKi初治者占55.4%。
  • 各药物疗程数:TNFi=3577,aIL-6R=1497,CTLA4-Ig=1139,JAKi=453。
  • 停药原因分为四类:无效、毒性不良事件、非毒性原因和缓解;采用多变量Cox比例风险模型分析停药HR。

主要发现

  • 因无效停药风险:TNFi的HR=1.93(95%CI:1.69至2.19),CTLA4-Ig的HR=1.42(95%CI:1.20至1.67),JAKi的HR=1.29(95%CI:1.03至1.63),均高于aIL-6R。
  • 因毒性不良事件停药风险:TNFi的HR=1.28(95%CI:1.05至1.56),aIL-6R的HR=1.27(95%CI:1.03至1.57),均高于CTLA4-Ig。
  • 基线合用口服糖皮质激素与TNFi因无效停药风险升高相关,HR=1.24(95%CI:1.09至1.41)。
  • 基线合用口服糖皮质激素与JAKi因毒性不良事件停药风险升高相关,HR=2.30(95%CI:1.23至4.28)。
  • 基线合用口服糖皮质激素与TNFi因毒性不良事件停药风险升高相关,HR=1.29(95%CI:1.07至1.55)。

关键数值与推荐

  • 因无效停药风险:TNFi的HR=1.93(95%CI:1.69至2.19),CTLA4-Ig的HR=1.42(95%CI:1.20至1.67),JAKi的HR=1.29(95%CI:1.03至1.63),均以aIL-6R为参照。
  • 因毒性不良事件停药风险:TNFi的HR=1.28(95%CI:1.05至1.56),aIL-6R的HR=1.27(95%CI:1.03至1.57),均以CTLA4-Ig为参照。
  • 总体停药风险(排除非毒性和缓解):TNFi的HR=1.52(95%CI:1.37至1.68),CTLA4-Ig的HR=1.14(95%CI:1.00至1.30),均以aIL-6R为参照。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: This multicentre retrospective study in Japan aimed to assess the retention of biological disease-modifying antirheumatic drugs and Janus kinase inhibitors (JAKi), and to clarify the factors affecting their retention in a real-world cohort of patients with rheumatoid arthritis. METHODS: The study included 6666 treatment courses (bDMARD-naïve or JAKi-naïve cases, 55.4%; tumour necrosis factor inhibitors (TNFi) = 3577; anti-interleukin-6 receptor antibodies (aIL-6R) = 1497; cytotoxic T lymphocyte-associated antigen-4-Ig (CTLA4-Ig) = 1139; JAKi=453 cases). The reasons for discontinuation were divided into four categories (ineffectiveness, toxic adverse events, non-toxic reasons and remission); multivariate Cox proportional hazards modelling by potential confounders was used to analyse the HRs of treatment discontinuation. RESULTS: TNFi (HR=1.93, 95% CI: 1.69 to 2.19), CTLA4-Ig (HR=1.42, 95% CI: 1.20 to 1.67) and JAKi (HR=1.29, 95% CI: 1.03 to 1.63) showed a higher discontinuation rate due to ineffectiveness than aIL-6R. TNFi (HR=1.28, 95% CI: 1.05 to 1.56) and aIL-6R (HR=1.27, 95% CI: 1.03 to 1.57) showed a higher discontinuation rate due to toxic adverse events than CTLA4-Ig. Concomitant use of oral glucocorticoids (GCs) at baseline was associated with higher discontinuation rate due to ineffectiveness in TNFi (HR=1.24, 95% CI: 1.09 to 1.41), as well as toxic adverse events in JAKi (HR=2.30, 95% CI: 1.23 to 4.28) and TNFi (HR=1.29, 95%CI: 1.07 to 1.55). CONCLUSIONS: TNFi (HR=1.52, 95% CI: 1.37 to 1.68) and CTLA4-Ig (HR=1.14, 95% CI: 1.00 to 1.30) showed a higher overall drug discontinuation rate, excluding non-toxicity and remission, than aIL-6R.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Ebina K, Etani Y, Maeda Y, et al. Drug retention of biologics and Janus kinase inhibitors in patients with rheumatoid arthritis: the ANSWER cohort study. RMD Open. 2023. PMID: 37597846. doi:10.1136/rmdopen-2023-003160

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。